Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
5 min read
Tolfenamic acid: Detailed Review of its Transformative R&D Success
26 October 2023
This article summarized the latest R&D progress of tolfenamic acid, the Mechanism of Action for tolfenamic acid, and the drug target R&D trends for tolfenamic acid.
Latest Hotspot
3 min read
Arvinas' two AR receptor PROTAC therapies show positive results in Phase 1/2 clinical trials
26 October 2023
Arvinas Inc. recently reported positive results for its AR-targeting protein degraders, bavdegalutamide (ARV-110) and ARV-766, in Phase 1/2 trials for mCRPC treatment at ESMO.
Drug Insights
4 min read
Taurolidine Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
26 October 2023
This article summarized the latest R&D progress of taurolidine, the Mechanism of Action for taurolidine, and the drug target R&D trends for taurolidine.
Bio Sequence
3 min read
Mapping the Evolution of the Competitive Landscape of Mirvetuximab Soravtansine
26 October 2023
In mapping the evolutionary trajectory of the patenting landscape pertaining to Mirvetuximab Soravtansine, it is critical to analyze the strategic approach of the top 10 assignees. There is also a dynamic shift in the competition blueprint that is dictated by the progression of time.
Drug Insights
5 min read
Unleashing the Power of tamibarotene: A Comprehensive Review on R&D Breakthroughs
26 October 2023
This article summarized the latest R&D progress of tamibarotene, the Mechanism of Action for tamibarotene, and the drug target R&D trends for tamibarotene.
Latest Hotspot
3 min read
Immutep announces positive clinical results for two studies of its novel LAG-3 immunotherapy, eftilagimod alpha
25 October 2023
Immutep recently introduced its novel LAG-3 immunotherapy, Eftilagimod Alpha (Efti), for cancer and autoimmune disease treatment at the 2023 ESMO meeting. It presented positive data from two trials for Efti with pembrolizumab ± double chemotherapy as first-line NSCLC treatments.
Drug Insights
5 min read
A Comprehensive Review of sunvozertinib's R&D Innovations and Drug Target Mechanism
25 October 2023
This article summarized the latest R&D progress of sunvozertinib, the Mechanism of Action for sunvozertinib, and the drug target R&D trends for sunvozertinib.
Valuable Targets
6 min read
Analysis on the Research Progress of p53 inhibitors
25 October 2023
p53 inhibitors interfere with the normal function of the p53 protein and are primarily used as research tools to study the biological effects of p53 inactivation.
Drug Insights
5 min read
Pharmaceutical Insights: sulfadiazine/trimethoprim's R&D Progress
25 October 2023
This article summarized the latest R&D progress of sulfadiazine/trimethoprim, the Mechanism of Action for sulfadiazine/trimethoprim, and the drug target R&D trends for sulfadiazine/trimethoprim.
Latest Hotspot
4 min read
Inxmed has announced two sets of data on FAK inhibitor Ifebemtinib
25 October 2023
Inxmed Co. announced that the significant clinical research results of its independently developed core product, Ifebemtinib (IN10018), the world's first small molecule FAK inhibitor.
Drug Insights
5 min read
Exploring rituximab-pvvr's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
25 October 2023
This article summarized the latest R&D progress of rituximab-pvvr, the Mechanism of Action for rituximab-pvvr, and the drug target R&D trends for rituximab-pvvr.
Valuable Targets
6 min read
Advances in Clinical Research on Nrf2 Inhibitor
25 October 2023
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a type of basic region-leucine zipper (bZIP) transcription factors, encoded by the NFE2L2 gene.